I-Candesartan CAS 139481-59-7 Ubumsulwa >99.0% (HPLC) Factory

Incazelo emfushane:

Igama Lekhemikhali: Candesartan

I-CAS: 139481-59-7

Ubumsulwa: >99.0% (HPLC)

Ukubukeka: Impushana Emhlophe

I-Angiotensin II Receptor Antagonist ekhethiwe

Ikhwalithi Ephezulu, Ukukhiqizwa Kwezohwebo

E-Mail: alvin@ruifuchem.com


Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali I-Candesartan
Omqondofana I-CV-11974;I-2-Ethoxy-1-[[2'- (1H-tetrazol-5-yl) [1,1'-biphenyl] -4-yl]methyl]-1H-Benzimidazole-7-Carboxylic Acid;3--[[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acid;I-Candesartan M1;Candesartan Cilexetil EP Impurity G
Inombolo ye-CAS 139481-59-7
Inombolo yeCAT I-RF-PI1889
Isimo Sesitoko Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula I-C24H20N6O3
Isisindo samangqamuzana 440.45
Ibhrendi I-Ruifu Chemical

Imininingwane:

Into Imininingwane
Ukubukeka Impushana Emhlophe
Identification-HPLC Isikhathi Sokugcina Esifana Nesejwayelekile
Ukuhlonza-IR Kufana ne-Standard
Ukuhlanzeka / Indlela Yokuhlaziya >99.0% (HPLC)
I-Melting Point 183.0~185.0℃
Ukulahlekelwa Ekumisweni <0.50%
Umswakama (KF) <0.50%
Izinsalela ekushiseni <0.50%
Izinsimbi Ezisindayo <20ppm
Ukungcola Ngamunye <1.00% (HPLC)
Ukungcola Okuphelele <1.00% (HPLC)
I-Refractive Index n20/D 1.745~1.747
Izinga Lokuhlola I-Enterprise Standard
Ukusetshenziswa I-API;Okokwelapha I-Hypertension

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

1

I-FAQ:

Isicelo:

I-Candesartan (i-CAS: 139481-59-7) iyisamukeli se-angiotensin II esine-IC50 ka-0.26 nM.Okuhlosiwe: I-Angiotensin II Receptor candesartan ikhonjiswe ekwelapheni umfutho wegazi ophakeme.I-Candesartan Cilexetil yavunywa okokuqala nge-GB ngo-Apr 29, 1997, yabe isigunyazwa yi-US Food and Drug Administration (FDA) ngoJuni 4, 1998, futhi yavunyelwa i-Pharmaceuticals and Medical Devices Agency of Japan (PMDA) ngo-Mar 12, 1999. Yathuthukiswa ngabakwa-AstraZeneca, yase imakethwa njenge-Atacand yi-AstraZeneca nge-GB nase-US, futhi imakethwa njenge-Blopress ngu-Takeda e-JP.I-Candesartan Cilexetil iyi-angiotensin II receptor blocker (ARB), ivimba imiphumela ye-vasoconstrictor kanye ne-aldosterone-secreting ye-angiotensin II ngokuvimbela ngokukhetha ukuboshwa kwe-angiotensin II ku-AT1 receptor ezicutshini eziningi, njenge-vascular smooth muscle kanye ne-adrenal gland.I-Atacand ikhonjiswe ekwelapheni umfutho wegazi ophakeme kubantu abadala kanye nezingane ezineminyaka engu-1 kuya kwezingu-17 ubudala, ukwehluleka kwenhliziyo (isigaba se-NYHA II-IV) futhi isetshenziselwe ukunciphisa ukufa kwenhliziyo nemithambo yegazi nokulaliswa esibhedlela.

Bhala umyalezo wakho lapha futhi usithumelele wona